Get the Stockscreener App
0.49
7.37%
-0.039
After Hours:
.49
Hepion Pharmaceuticals Inc stock is traded at $0.49, with a volume of 48,091.
It is down -7.37% in the last 24 hours and down -29.43% over the past month.
Hepion Pharmaceuticals Inc is a biopharmaceutical company that focuses primarily on the development of drug therapy for the treatment of chronic liver diseases. This therapeutic approach targets fibrosis and hepatocellular carcinoma associated with non-alcoholic steatohepatitis, viral hepatitis, and other liver diseases. Its cyclophilin inhibitor, Rencofilstat, is being developed to offer benefits to address these multiple complex pathologies. Rencofilstat is a pan-cyclophilin inhibitor that targets multiple pathologic pathways involved in the progression of liver disease.
See More
Previous Close:
$0.529
Open:
$0.5
24h Volume:
48,091
Relative Volume:
1.13
Market Cap:
$3.41M
Revenue:
-
Net Income/Loss:
$-44.68M
P/E Ratio:
-0.041
EPS:
-11.96
Net Cash Flow:
$-36.70M
1W Performance:
-16.95%
1M Performance:
-29.43%
6M Performance:
-51.96%
1Y Performance:
-83.28%
1-Day Range:
$0.4801
$0.53
1-Week Range:
$0.4801
$0.599
52-Week Range:
$0.4777
$3.72
Hepion Pharmaceuticals Inc Stock (HEPA) Company Profile
Name
Hepion Pharmaceuticals Inc
Sector
Industry
Phone
732-902-4000
Address
399 THORNALL STREET, EDISON
Compare HEPA with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
HEPA
Hepion Pharmaceuticals Inc
|
0.49 | 3.41M | 0 | -44.68M | -36.70M | -12.42 |
|
VRTX
Vertex Pharmaceuticals Inc
|
397.27 | 102.31B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
701.85 | 77.13B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
623.82 | 37.30B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
245.44 | 31.66B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
113.08 | 27.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Hepion Pharmaceuticals Inc Stock (HEPA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-20-20 | Resumed | ROTH Capital | Buy |
Hepion Pharmaceuticals Inc Stock (HEPA) Latest News
Comparing Novo Nordisk A/S (NYSE:NVO) and Hepion Pharmaceuticals (NASDAQ:HEPA) - Defense World
HEPA stock touches 52-week low at $0.49 amid market challenges By Investing.com - Investing.com South Africa
HEPAHepion Pharmaceuticals, Inc. Latest Stock News & Market Updates - StockTitan
Hepion Pharmaceuticals Terminates Merger with Pharma Two B - TipRanks
HEPA stock touches 52-week low at $0.49 amid market challenges - Investing.com
Hepion Pharmaceuticals cancels merger and stockholder meeting By Investing.com - Investing.com Canada
Hepion Pharmaceuticals, Inc. Announces Termination of Merger Agreement with Pharma Two B Ltd. - The Manila Times
Hepion Pharmaceuticals Terminates Strategic Merger with Pharma Two BMajor Deal Cancelled - StockTitan
Hepion Pharmaceuticals (NASDAQ:HEPA) Stock Quotes, Forecast and News Summary - Benzinga
Oligonucleotide Therapy Market Key Players AnalysisBPCI - openPR
Pharma Two B Announces Poster Presentation on P2B001 at the - GlobeNewswire
Hepion Pharmaceuticals (NASDAQ:HEPA) Shares Down 4.1% – Here’s What Happened - Defense World
Hepion urges shareholder support for Pharma Two B merger - Investing.com India
Hepion urges shareholder support for Pharma Two B merger By Investing.com - Investing.com Canada
Hepion Pharmaceuticals Issues Letter to Shareholders Urging Support for Proposed Merger with Pharma Two B - The Manila Times
Hepion Pharma Urges Shareholder Support for Merger Amid Financial Challenges - StockTitan
Hepion Pharmaceuticals faces Nasdaq delisting risk By Investing.com - Investing.com Nigeria
Hepion Pharmaceuticals faces Nasdaq delisting risk - Investing.com India
HEPA (Hepion Pharmaceuticals) 3-Year EPS without NRI Growth Rate : 35.30% (As of Sep. 2024) - GuruFocus.com
HEPA (Hepion Pharmaceuticals) Accounts Receivable : $0.00 Mil (As of Sep. 2024) - GuruFocus.com
HEPA (Hepion Pharmaceuticals) Long-Term Debt & Capital Leas - GuruFocus.com
HEPA (Hepion Pharmaceuticals) Days Inventory : 0.00 (As of Sep. 2024) - GuruFocus.com
HEPA (Hepion Pharmaceuticals) 5-Year Dividend Growth Rate : 0.00% (As of Sep. 2024) - GuruFocus.com
Analysis of ARMISTICE CAPITAL, LLC's Recent Transaction in Hepio - GuruFocus.com
Hepion Pharmaceuticals Inc (CTVRP) Quarterly 10-Q Report - Quartzy
Hepion Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Pharma Two B and Hepion Pharmaceuticals, Inc. Announce Effectiveness of Registration Statement Related to Proposed Merger - The Manila Times
Pharma Two B and Hepion Pharmaceuticals, Inc. Announce - GlobeNewswire
Hepion & Pharma Two B Merger Advances: SEC Approves Key Registration for $HEPA Deal | HEPA Stock News - StockTitan
U.S. stocks higher at close of trade; Dow Jones Industrial Average up 0.67% - MSN
Non Alcoholic Fatty Liver Disease (NAFLD) Clinical Trials 2024: EMA, PDMA, FDA Approvals, Medication, Statistics, Drugs, Mechanism of Action, Route of Administration, and Companies by DelveInsight - The Globe and Mail
Will Hepion's AMBITION Be Fulfilled? - RTTNews
Phathom Pharmaceuticals (NASDAQ:PHAT) Shares Down 4% - MarketBeat
Hypha Labs, Inc. Releases Investor Presentation - AccessWire
Does Hyliion Holdings Corporation (NYSE: HYLN) Still Need To Convince Analysts? - Stocks Register
FluoRok raises US$ 9.8million for safety and sustainability of fluorochemical production - Indian Chemical News
FLO stock rated an Underperform by Exane BNP Paribas - Knox Daily
Barrow Hanley Mewhinney & Strauss LLC Purchases Shares of 898,419 Helios Technologies, Inc. (NASDAQ:HLIO) - MarketBeat
Hancock Whitney Corp Buys 10,920 Shares of PHINIA Inc. (NYSE:PHIN) - MarketBeat
FluoRok Raises £7.7M in Funding - FinSMEs
Oxford's FluoRok secures €9.2M from BGF and others - Silicon Canals
HilleVax, Inc. (NASDAQ:HLVX) Given Consensus Rating of “Hold” by Analysts - Defense World
PHINIA Inc. (NYSE:PHIN) Shares Acquired by Long Road Investment Counsel LLC - Defense World
King Luther Capital Management Corp Boosts Position in Helios Technologies, Inc. (NASDAQ:HLIO) - Defense World
Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA) Short Interest Update - Defense World
Hepion Pharmaceuticals faces Nasdaq delisting over share price - Investing.com
Hepion Pharmaceuticals faces Nasdaq delisting over share price By Investing.com - Investing.com Canada
Pharma Two B and Hepion Pharmaceuticals file for merger - Investing.com
Pharma Two B and Hepion Pharmaceuticals file for merger By Investing.com - Investing.com UK
Hepion, Pharma Two B file registration statement for proposed merger - TipRanks
Pharma Two B and Hepion Pharmaceuticals, Inc. Announce Filing of Registration Statement on Form F-4 Related to Proposed Merger - ForexTV.com
Hepion Pharmaceuticals Inc Stock (HEPA) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.88%
2.65%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):